Literature DB >> 32283037

C1q/Tumor Necrosis Factor-Related Protein-9 Attenuates Diabetic Nephropathy and Kidney Fibrosis in db/db Mice.

Hongyao Hu1, Wei Li2,3,4, Mingxin Liu2,3,4, Jiarui Xiong2,3,4, Yanjun Li2,3,4, Yanzhao Wei2,3,4, Congxin Huang2,3,4, Yanhong Tang2,3,4.   

Abstract

Diabetic nephropathy (DN) is characterized by excessive accumulation of extracellular matrix leading to early thickening of glomerular and tubular basement membrane. C1q/tumor necrosis factor (TNF)-related protein-9 (CTRP9) was recently identified as an adiponectin paralog of superior prominence. CTRP9 is an anti-inflammatory, antioxidant, vasodilation and atheroprotective adipose cytokine that share a similar metabolic regulatory function as adiponectin. Additionally, CTRP9 inhibits apoptosis of endothelial cells, decreases blood glucose level, and increases insulin sensitivity. However, the renoprotective effects of CTRP9 and the underlying molecular mechanisms in DN have not been explored. This study examined the effects of CTRP9 on DN in diabetic db/db mice through adenovirus-mediated overexpression. From the results, CTRP9 ameliorated renal dysfunction and injury at the structural and functional level in diabetic db/db mice. Additionally, CTRP9 inhibited glomerular and tubular glycogen accumulation, fibrosis, relieved hyperglycemia-mediated oxidative stress, and apoptosis. This is the first study to report on therapeutic effects of CTRP9 on DN, presenting a potentially effective clinical treatment method for DN patients.

Entities:  

Keywords:  CTRP9; apoptosis; diabetic nephropathy (DN); fibrosis; oxidative stress

Year:  2020        PMID: 32283037     DOI: 10.1089/dna.2019.5302

Source DB:  PubMed          Journal:  DNA Cell Biol        ISSN: 1044-5498            Impact factor:   3.311


  8 in total

1.  CTRP9 protects against MIA-induced inflammation and knee cartilage damage by deactivating the MAPK/NF-κB pathway in rats with osteoarthritis.

Authors:  Shicheng Zheng; Jing Ren; Sihai Gong; Feng Qiao; Jinlong He
Journal:  Open Life Sci       Date:  2020-12-23       Impact factor: 0.938

2.  C1q/TNF-Related Protein 9 Attenuates Atherosclerosis by Inhibiting Hyperglycemia-Induced Endothelial Cell Senescence Through the AMPKα/KLF4 Signaling Pathway.

Authors:  Gang Wang; Baihe Han; Ruoxi Zhang; Qi Liu; Xuedong Wang; Xingtao Huang; Dandan Liu; Weishen Qiao; Mengyue Yang; Xing Luo; Jingbo Hou; Bo Yu
Journal:  Front Pharmacol       Date:  2021-10-22       Impact factor: 5.810

3.  CTRP9 decreases high glucose‑induced trophoblast cell damage by reducing endoplasmic reticulum stress.

Authors:  Lianxiao Zhang; Huiqing Ding; Yubo Shi; Duoyi Zhang; Xue Yang
Journal:  Mol Med Rep       Date:  2022-03-29       Impact factor: 2.952

Review 4.  C1q/Tumor Necrosis Factor-Related Protein 9: Basics and Therapeutic Potentials.

Authors:  Hua Guan; Yanli Wang; Xiangyu Li; Aoqi Xiang; Fengwei Guo; Jianglin Fan; Qi Yu
Journal:  Front Physiol       Date:  2022-03-18       Impact factor: 4.566

Review 5.  Putative therapeutic impacts of cardiac CTRP9 in ischaemia/reperfusion injury.

Authors:  Seyyed-Reza Sadat-Ebrahimi; Hassan Amini; Reza Rahbarghazi; Paria Habibollahi; Shahrouz Ghaderi; Hadi Rajabi; Aysa Rezabakhsh
Journal:  J Cell Mol Med       Date:  2022-05-10       Impact factor: 5.295

6.  C1q/TNF-related Protein 9 Inhibits High Glucose-Induced Oxidative Stress and Apoptosis in Retinal Pigment Epithelial Cells Through the Activation of AMPK/Nrf2 Signaling Pathway.

Authors:  Yuhong Cheng; Yun Qi; Siwei Liu; Rong Di; Qiang Shi; Jiayu Li; Cheng Pei
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

7.  Association of serum CTRP9 levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus.

Authors:  Junpeng Yang; Dongni Zhao; Yi Chen; Yuehua Ma; Xiaoyang Shi; Xiaobing Wang; Yinghua Lv; Huijuan Yuan
Journal:  J Diabetes Investig       Date:  2021-02-05       Impact factor: 4.232

Review 8.  GSDMD-mediated pyroptosis: a critical mechanism of diabetic nephropathy.

Authors:  Yi Zuo; Li Chen; Huiping Gu; Xiaoyun He; Zhen Ye; Zhao Wang; Qixiang Shao; Caiping Xue
Journal:  Expert Rev Mol Med       Date:  2021-12-27       Impact factor: 5.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.